Impact of adverse events on survival outcomes in patients treated with CDK4/6 inhibitors for advanced breast cancer
CDK4/6 inhibitors have distinct toxicity profiles. Effective AE management and dose adjustments are crucial for maintaining efficacy, emphasizing the need for AE prediction models to optimize CDK4/6i use in HR + HER2 - aBC.
Authors
- Irene De Gennaro Aquino
- Daniele Generali (ORCID: https://orcid.org/0000-0003-2480-3855)
- A. Crastes de Paulet (ORCID: https://orcid.org/0009-0002-8498-9719)
- D. Ravizza (ORCID: https://orcid.org/0000-0001-7896-7295)
- Giandomenico Roviello (ORCID: https://orcid.org/0000-0001-5504-8237)
- Claudia De Angelis (ORCID: https://orcid.org/0000-0003-0398-5610)
- Roberto Petrioli
- M. Catalano (ORCID: https://orcid.org/0000-0002-8355-0344)
- Kristian Shtembari
- Gestiana Cekrezi
Institutions
- University of Siena (IT)
- University of Trieste (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Istituti Ospitalieri di Cremona (IT)
- University of Florence (IT)
Publication Details
- Journal
- Cancer Chemotherapy and Pharmacology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1007/s00280-025-04836-y
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00